

<b>PATENT ASSIGNMENT COVER SHEET</b>
--------------------------------------

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT5160869

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
TEVA PHARMACEUTICAL INDUSTRIES LTD.	09/20/2018
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.
<b>Street Address:</b>	JERUSALEM BIOPARK, HADASSAH EIN KEREM MEDICAL CENTER, P.O. BOX 12000
<b>City:</b>	JERUSALEM
<b>State/Country:</b>	ISRAEL
<b>Postal Code:</b>	9112001
<b>PROPERTY NUMBERS Total: 1</b>	
<b>Property Type</b>	<b>Number</b>
<b>Application Number:</b>	13455932
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(703)415-4864
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	(703) 859-9634
<b>Email:</b>	martin@ipatent.co.il
<b>Correspondent Name:</b>	MARTIN D. MOYNIHAN
<b>Address Line 1:</b>	P.O. BOX 16446
<b>Address Line 2:</b>	PRTSI, INC.
<b>Address Line 4:</b>	ARLINGTON, VIRGINIA 22215
<b>ATTORNEY DOCKET NUMBER:</b>	74284
<b>NAME OF SUBMITTER:</b>	MARTIN D. MOYNIHAN
<b>SIGNATURE:</b>	/Martin D. Moynihan/
<b>DATE SIGNED:</b>	09/27/2018
<b>Total Attachments: 1</b>	
source=74284 Executed Assignment from Teva Pharmaceutical Industries Ltd. to Hadasit#page1.tif	

ASSIGNMENT

For good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the undersigned (hereinafter called the "Assignor"):

**Teva Pharmaceutical Industries Ltd.**  
5 Basel Street  
49510 Petah Tikva  
Israel

hereby sell(s), assign(s) and transfer(s) to:

**Hadasit Medical Research Services and Development Ltd.**  
Jerusalem BioPark  
Hadassah Ein Kerem Medical Center  
P.O. Box 12000  
9112001 Jerusalem  
Israel

(hereinafter called the "Assignee"), its successors, assigns, nominees or other legal representatives, the undersigned's entire rights, title and interest in and to the invention titled:

**FORMULATIONS OF 6-MERCAPTOPYRIMIDINE**

described and claimed in the following Patent Application:

**US Patent No. 8,188,067,**  
**issued on May 29, 2012,**  
**and identified as Attorney Docket No. 74283**

and in and to said Patent Application, and all original and reissued Patents granted therefore, and all divisions and continuations thereof, any corresponding PCT Patent Application and the National Phases thereof, including the right to apply and obtain Patents in all other countries, the right to claim priority under International Conventions, and the Letters Patent which may be granted thereon:


covenant that the undersigned have (has) the full right to convey the entire interest therein assigned;


authorize(s) and request(s) the Registrar of Patents, and any Official of any country whose duty it is to issue Patents on applications as aforesaid, to issue the said Letters Patent to the said Assignee;

and agree(s) to sign all lawful papers, make all rightful oaths, do all lawful acts requisite for such Patent Applications, and do everything possible to aid said Assignee to apply for, obtain and enforce Patent protection for said invention.

**ASSIGNOR**

**Teva Pharmaceutical Industries Ltd.**

Signature :   
Name : **Sharon F. Hausdorff, Ph.D.**  
VP and Chief Patent Counsel  
Capacity : \_\_\_\_\_  
Date : Sep 20th 2018

  
**Naomi Zingboim, Adv**  
Director Executive Patent Counsel